Residual ethylene oxide (EO) determination is an essential safety test for medical devices sterilized with ethylene oxide gas, ensuring that toxic residues of EO and its by-products remain below biologically safe limits before products reach patients. This article provides a comprehensive technical overview of the governing standards, including ISO 10993-7 and GB/T 16886.7, the analytical methods based on headspace gas chromatography, and the acceptance criteria applied by accredited third-party laboratories.
Technical Overview
Ethylene oxide (EO) sterilization is a low-temperature gaseous process widely used for medical devices that are sensitive to heat and moisture, including polymer-based consumables, combination products, and devices packaged in complex sterile barrier systems. However, EO and its principal reaction by-products, ethylene chlorohydrin (ECH, 2-chloroethanol) and ethylene glycol (EG), are toxic, irritating, sensitizing, and genotoxic, and EO itself is classified as a known human carcinogen. Residual amounts of these substances can diffuse out of the device during clinical use and expose patients to unacceptable risk.
Residual EO evaluation is governed primarily by ISO 10993-7 (Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals), which is adopted in Europe as EN ISO 10993-7 and in China as GB/T 16886.7. For infusion, transfusion, and injection equipment, GB/T 14233.1 specifies dedicated chemical analysis methods, including headspace gas chromatographic procedures for EO residues. Sterilization process development and routine control are addressed in ISO 11135, while ISO 10993-17 and ISO 10993-18 provide supporting frameworks for establishing allowable limits and for chemical characterization of extractables.
Accredited third-party laboratories performing this testing typically operate under ISO/IEC 17025 quality systems and apply validated headspace gas chromatography (HS-GC) techniques with flame ionization detection (FID) or mass spectrometric detection (MS), combined with extraction procedures that either simulate clinical use or exhaustively extract the total residue burden from the device.
Testing Samples
Sterile Single-Use Consumables
Syringes, hypodermic needles, infusion and transfusion sets, intravenous cannulae, stopcocks, drainage bags, and injection accessories, which represent the highest-volume category of EO-sterilized products and are frequently tested for lot release.
Implantable and Long-Contact Devices
Hernia repair meshes, cardiac occluders, absorbable hemostatic materials, intraocular lenses, dental materials, and other implants for which contact duration exceeds 24 hours and permanent-contact limits may apply.
Extracorporeal Circulation Products
Hemodialyzers, blood oxygenators, extracorporeal blood tubing sets, and blood filters, which are covered by special limit categories in ISO 10993-7 due to large blood-contacting surface areas.
Wound Management Products
Gauze dressings, non-woven and foam dressings, hydrocolloid and film dressings, tissue adhesives, and negative-pressure wound therapy kits.
Respiratory and Anesthesia Devices
Breathing circuits, endotracheal tubes, laryngeal mask airways, anesthesia breathing filters, and humidification chambers.
In Vitro Diagnostic Consumables
Sterile sample collection tubes, swabs, transfer pipettes, pipette tips, and cuvettes where EO sterilization is used and residual safety must be demonstrated.
Testing Items
The core test items for an EO residue study typically include:
- Residual ethylene oxide (EO) content, reported in mg per device or µg per gram of product.
- Residual ethylene chlorohydrin (ECH) content, reported in the same units and evaluated against its own tolerable exposure limits.
- Ethylene glycol (EG) determination, where the sterilization process or materials indicate significant formation of this degradation product.
- Extract concentration (µg/mL) from simulated-use extraction, used to estimate the deliverable dose to the patient.
- Comparison of measured residues against the contact-duration limits of ISO 10993-7 and GB/T 16886.7.
The principal acceptance criteria from ISO 10993-7 and GB/T 16886.7 for an average delivered dose to a patient over the exposure period are:
- Limited contact (up to 24 hours): EO not more than 4 mg; ECH not more than 5 mg.
- Prolonged contact (24 hours to 30 days): EO not more than 2 mg; ECH not more than 5 mg.
- Permanent contact (more than 30 days): EO not more than 0.1 mg; ECH not more than 2 mg.
- Intraocular lenses: EO not more than 0.5 µg and ECH not more than 5 µg per lens.
- Extracorporeal blood oxygenators: EO not more than 20 mg per device.
Testing Methods
Sample Collection and Storage
Finished sterile devices are sampled after completion of the full aeration cycle and placed without delay into airtight containers, typically sealed glass vessels or headspace vials with minimal free volume, to prevent loss of volatile residues. Samples are transported and stored under cool conditions and analyzed promptly to preserve residue integrity.
Extraction Procedures
Two complementary extraction strategies are recognized. Simulated-use extraction immerses the whole device or a representative portion in water in a sealed vessel at 37 ± 1 °C for 1 hour, approximating the amount of residue a patient could actually receive during clinical use. Exhaustive extraction repeatedly extracts the sample until the residue in a subsequent extract is less than 10 percent of the first, providing the total residue burden. The choice between the two must be justified according to the intended use and contact scenario defined in ISO 10993-7.
Headspace Gas Chromatography with Flame Ionization Detection
Headspace GC-FID is the primary quantitative technique. Aliquots of the extract are sealed in headspace vials, equilibrated typically at 80 °C for 30 to 45 minutes to partition EO into the gas phase, and injected onto a mid-polar capillary column, such as a 6% cyanopropylphenyl and 94% dimethylpolysiloxane phase (30 m × 0.32 mm × 1.8 µm), which provides baseline separation of EO and ECH. Quantification is performed by external calibration using standard solutions of EO and ECH prepared in water, and results are converted to mg per device using dilution factors, extraction volumes, and device mass or quantity.
GC-MS Confirmation
Gas chromatography-mass spectrometry is used for confirmation of peak identity in complex matrices, for investigation of interferences, and for achieving lower detection limits when devices must comply with stringent permanent-contact or special-device limits.
Method Validation and Quality Control
Methods are validated in accordance with ISO/IEC 17025 requirements, covering linearity across the working range (typically r² not less than 0.995), limits of detection and quantification, recovery from spiked matrix samples (typically 80 to 120 percent), and repeatability (relative standard deviation generally not more than 10 percent). Reagent blanks, duplicate analyses, and continuing calibration verification are included in each analytical batch.
Applications
Residual EO determination supports multiple regulatory and quality objectives across the medical device lifecycle:
- Regulatory registration submissions, including technical documentation for market approval in China, the United States, and the European Union, where EO residue data are a standard requirement for EO-sterilized devices.
- Sterilization process validation under ISO 11135, demonstrating that specified aeration cycles consistently reduce residues to acceptable levels.
- Aeration cycle optimization, by comparing residual profiles at different aeration times, temperatures, and load configurations to shorten cycle duration without compromising safety.
- Routine batch release testing for high-risk product families as part of the manufacturer's quality control plan.
- Shelf-life and stability studies, verifying that residues remain within limits throughout the labeled expiry period.
- Change control evaluation when materials, adhesives, packaging configurations, or sterilization loads are modified.
- Post-market surveillance, complaint investigation, and root-cause analysis following adverse events associated with EO-sterilized products.
FAQ
What is the maximum allowable EO residue in a medical device?
Under ISO 10993-7 and GB/T 16886.7, the average delivered EO dose must not exceed 4 mg for devices contacting the patient for less than 24 hours, 2 mg for contact between 24 hours and 30 days, and 0.1 mg for permanent devices. Parallel limits of 5 mg, 5 mg, and 2 mg apply to ECH, with stricter special limits for intraocular lenses and blood oxygenators.
Why is headspace gas chromatography the preferred technique?
EO is highly volatile, and static headspace sampling introduces only the vapor phase into the chromatograph, avoiding contamination of the inlet and column by non-volatile extract components. The technique offers excellent sensitivity, reproducibility, and specificity for EO and ECH in aqueous extracts and is the reference approach described in the annexes of ISO 10993-7 and in GB/T 14233.1.
When should residual testing be performed relative to sterilization?
Testing should be performed after completion of the validated aeration cycle, ideally at the earliest point at which the product could be distributed to market, because residues continue to decrease over time. This worst-case timing provides the most conservative assessment of patient exposure.
How many samples and batches should be tested?
For process validation and registration purposes, testing typically covers three consecutive production or validation batches, with replicate samples analyzed from each batch. The exact sampling plan depends on the validation protocol, product risk classification, and regulatory expectations.
What is the difference between simulated-use and exhaustive extraction?
Simulated-use extraction estimates the residue actually delivered to a patient under clinical conditions, using mild aqueous extraction at body temperature, and is appropriate for most short-contact devices. Exhaustive extraction removes essentially all residual EO and ECH from the product and is required when a conservative total-residue assessment is needed or when simulated-use conditions cannot be justified.
How can manufacturers reduce EO residuals?
Effective measures include extending aeration time, moderately increasing aeration temperature within material tolerance, using breathable primary packaging, reducing load density and packaging mass in the sterilizer, selecting lower-absorbing polymeric materials, and optimizing sterilant exposure and vacuum profiles in accordance with ISO 11135.